AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01486888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Study NCT01486888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
Study NCT00872300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHA-739358
Description: Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
Study NCT03498417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum antibodies against the IGF-1R
Description: Measurement of antibodies against the IGF-1R in serum samples by ELISA
Study NCT03589105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 300 mg
Description: Two doses of 300 mg infusion administered 14 days apart.
Study NCT01812057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg IV (as a one time dose)
Study NCT03589105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg
Description: A single does of 600 mg infusion administered 24 weeks after the initial dose.
Study NCT03629392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low met/cys diet
Description: Dietary intervention with low contents of methionine and cysteine
Study NCT03629392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate met/cys diet
Description: Dietary intervention with moderate contents of methionine and cysteine
Study NCT01812057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% -5 ml
Study NCT03832738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451 Tablets
Description: Active drug tablets containing JTE-451
Study NCT03832738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo tablets matching in appearance to the active drug tablets
Study NCT01758146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg once daily for 5 years
Study NCT01758146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letroz, Femara, Letronat
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry bipolar radiofrequency (RF) clamp
Description: Specified device used for ablation during standard surgical procedure
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar microwave antenna
Description: Specified device used for ablation during standard surgical procedure
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar cryothermic probe
Description: Specified device used for ablation during standard surgical procedure
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigated unipolar RF antenna
Description: Specified device used for ablation during standard surgical procedure
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigated bipolar RF clamp
Description: Specified device used for ablation during standard surgical procedure
Study NCT03377660 — intervention group
Intervention type: OTHER
Intervention: Clinical treatment
Description: Patients undergo clinical treatment as indicated, they are studied before and after.
Study NCT03140618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The light and environment project in psychiatric inpatient care
Description: Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built.
Study NCT00466973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hi-intensity focused ultrasound wand
Description: Specified device used for ablation during standard surgical procedure
Study NCT05595746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Description: In dental implant placement surgery, first of all, intraoral infiltrative anesthesia is applied to the area. After the crestal incision, the buccal flap is elevated to full thickness. Vertical mucosal height is measured with a William type standard periodontal probe. The palatal/lingual flap is then elevated to full thickness. The implant is placed at different levels with the standard protocol determined by the manufacturer. Study groups are determined by the placement levels of the implants and the vertical mucosal height measurement values. After the implants are placed, the flap is closed primarily.
Study NCT02588885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-sensitive Care
Description: Psychological intervention~1. education~2. empowerment~3. desensitization~4. relaxation tools~Physical therapy intervention~1. techniques to address muscular tension~2. empowerment~3. comfort~4. encouragement of trauma-related coping skills
Study NCT00048984 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02378597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Resiliency Intervention
Description: 4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
Study NCT04108923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure
Description: the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
Study NCT04108923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vessel ligation
Description: Conventional vessel ligation either tying and /or clipping of blood vessels
Study NCT02481557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxalate Salt Solution
Description: Applied by dentist
Study NCT02647684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Triple P
Description: 10 Week Triple P Self directed workbook
Study NCT04546100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal-Infant Exercise Program
Description: Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise.
Study NCT01819324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeting the Teachable Moment
Description: TTMI material (every other week for 4 months)
Study NCT01819324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Lifestyle Management
Description: SLM material (every other week for 4 months)
Study NCT02350582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation eCUIDATE system
Description: Resistence and endurance exercise adapted to individual requeriment during chemotherapy
Study NCT00754013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (Donepezil hydrochloride)
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally.
Study NCT00754013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally.
Study NCT00131638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
Study NCT00131638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
Study NCT04056039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
Study NCT04056039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
Study NCT02825368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR
Description: 0.5 mL, subcutaneous
Study NCT02825368 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: 0.5 mL, intramuscular
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diphtherinum®
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pertussinum®
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tetanotxicum®
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morbilinum®
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ourlianum®
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: 0.5 mL, intramuscular
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile saline
Description: 0.5 mL, intramuscular
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pellets
Study NCT02825368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pellets
Study NCT06414850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal Assisted Therapy (AAT)
Description: A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
Study NCT06414850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy (AAT)
Description: A structured AAT program and pharmacological treatment in Experimental group. The same structured program without therapy dog and pharmacological treatment in Control group.
Study NCT01337635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
Study NCT00989937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID
Study NCT00989937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID
Study NCT00989937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 IU BID or 40 IU BID
Study NCT00989937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 IU BID or 40 IU BID
Study NCT02135042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03026907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alitretinoin
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Study NCT03026907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
Study NCT03182894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)
Description: Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
Study NCT04186598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask system
Description: Intervention group will receive 15cm of H2O of positive end expiratory pressure
Study NCT04186598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine 30 MG
Description: All participants will receive this intervention
Study NCT04186598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 MG
Description: All participants will receive this intervention
Study NCT04186598 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP mask system without PEEP
Description: Placebo group will receive high flow oxygen via altered CPAP mask system without providing any positive end expiratory pressure
Study NCT01859767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]MNI-672 SPECT
Description: Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
Study NCT04462016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calamansi
Description: 250 ml of a commercially sourced calamansi drink
Study NCT04462016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75 g of glucose dissolved in 250 ml of drinking water
Study NCT04900909 — intervention group
Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves
Study NCT00991731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Faith-based
Description: The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
Study NCT00991731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-faith-based
Description: The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
Study NCT04546100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maternal-Infant Exercise Program
Description: Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise.
Study NCT01901536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations Coparenting Program
Description: Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff.
Study NCT02135042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00188214 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced dynamic CT perfusion study
Description: contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
Study NCT00740181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT01378117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 50-100mg po once daily
Study NCT01378117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: glargine once daily
Study NCT01378117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lispro
Description: lispro before meals
Study NCT03767049 — intervention group
Intervention type: OTHER
Intervention: Colection of clinical data
Description: Colection of clinical data
Study NCT01656161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin embonate 22.5 mg
Study NCT03053128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy
Description: Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
Study NCT03053128 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham cardiac shock wave (Control group)
Description: Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
Study NCT00226005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTK787/ZK222584
Description: One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Study NCT01527630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
Study NCT02315547 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotics
Description: Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
Study NCT04208269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postcard campaign
Description: Post card sent to parent only
Study NCT01074125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
Study NCT04052009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional gait training
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms